59 results about "EDEMA RETINAL" patented technology

According to the maculopathy diagnosis device and method based on GCN and Mama cooperation and the medium, feature interaction processing is carried out by designing a GMMN module (a graph mapping Mama network), each pixel is regarded as a feature node, and through combination of graph convolution and Mama coding, the advantages of the two methods are brought into full play, and the respective limitations of the two methods are overcome at the same time. Furthermore, a mapping module is developed, and effective cross-branch feature fusion is realized by using a geometrical relationship between feature nodes. A large number of experimental results prove that the network has excellent performance when the CFP modal image is used for automatic diagnosis of macular edema, and the effectiveness and clinical application potential of the method are verified. According to experimental verification on two public data sets of IDRID and Messidor and one private data set, 91.26%, 94.58% and 98.43% of diagnosis accuracy are achieved respectively, it is indicated that the method can achieve a good diagnosis effect on different data sets, and the huge potential of the method in clinical application is highlighted.

According to the macular oedema diagnosis system, method and device based on color fundus photography, the medium and the program product, the bright part enhancement and dark part enhancement of the CFP image are combined, the problem that diagnosis is difficult due to the fact that macular oedema features are not obvious in traditional CFP image diagnosis is solved, and the diagnosis accuracy and efficiency are greatly improved. Experimental results show that the accuracy rate of the method can reach 95% or above on a private data set, and the accuracy rate of multi-stage diagnosis of macular edema on a public macular degeneration and macular edema combined data set IDRID can reach 85%. Besides, a Mama layer in an SSM (Spatial-Sense-Modulation) framework is adopted to perform global feature modeling, so that the capability of capturing the global relationship of the image is further improved, the bottleneck problem encountered in actual clinical application due to the fact that a Transform model depends on computing resources is reduced, the requirement for high-performance computing equipment is reduced, and the method has the advantages of being high in practicability and easy to popularize. And possibility is provided for application in areas with limited resources.

The present disclosure relates to fusion molecules and chimeric molecules which comprise two components: an Ang-2 antagonist peptide linked to a VEGF-binding moiety. Further disclosed are methods of using said chimeric molecules to treat a patient cancer, proliferative retinopathy, neovascular glaucoma, macular edema, wet age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), or diabetic retinopathy (DR).

The present invention provides a compound of Formula Iand pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

The invention provides extracellular vesicle proteins sPTPRG and Vincin of a biomarker for detecting retinal vein obstructive macular edema (RVO-ME) anti-VEGF treatment typing, the difference of the expression quantity of the extracellular vesicle proteins in aqueous humor of a patient is analyzed, the protein with remarkable expression difference is screened out, the protein can be used as the biomarker for RVO-ME treatment, and the application of the biomarker for detecting the anti-VEGF treatment typing of the retinal vein obstructive macular edema (RVO-ME) anti-VEGF treatment typing of the RVO-ME anti-VEGF treatment typing is facilitated. Important guidance is provided for personalized treatment of RVO-ME, and the method has a wide clinical application prospect.

The present invention relates to antibodies that bind to VEGF and ANG2 for use in the treatment of ocular vascular diseases, such as neovascular AMD (nAMD) (also referred to as choroidal angiogenesis [CNV] secondary to age-related macular degeneration [AMD] or wet AMD), diabetic retinopathy, in particular diabetic macular edema (DME) or macular edema secondary to retinal vein occlusion (RVO).

The present invention relates to methods, devices, and compositions for treating macular edema associated with non-infectious uveitis. For example, the methods include treatment of certain populations of subjects having macular edema associated with non-infectious uveitis by administering to the subjects a triamcinolone composition via non-surgical administration to the suprachoroidal space (SCS) of the eye.

The present disclosure relates to methods for improving vision of a patient by administering a blended composition, particularly in the form of a dietary supplement. The method addresses various impairments, including macular degeneration, presbyopia, macular edema, cataracts, glaucoma, blurred vision and temporal arteritis.

The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.

The invention is concerned with a method of predicting response to an IL-6 angatonist such as anti-IL-6 antibody by determing the concentration of IL-6 in human aqueous humor. The invention is also concerned with an IL-6 angatonist for use in treatment of uveitis or uveitic macular edema.

The present invention relates to 3, 5-diaminotriazole derivatives of formula (I) and pharmaceutical or veterinary compositions comprising such derivatives. It further relates to the use of the compounds of formula (I) for the treatment of ocular diseases, preferably diabetic retinopathy, macular degeneration, neovascular glaucoma, macular edema or Steckstroke disease.

3-[(3S,4R)-3-Methyl-6-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile suppresses an increase of the retinal vascular permeability induced by VEGF, it can be used as an active ingredient of a therapeutic or preventive agent for various eye diseases involving VEGF, such as age-related macular degeneration, diabetic retinopathy, macular edema, neovascular maculopathy, retinal vein occlusion and neovascular glaucoma.

The present invention relates to a method of predicting response to an IL-6 antagonist, such as an anti-IL-6 antibody, by determining the concentration of IL-6 in human aqueous humor. The invention also relates to an IL-6 antagonist for use in the treatment of uveitis or uveitis macular edema.

The present invention relates to a method for the production of an ocular implant, wherein dexamethasone — commonly employed in the treatment of macular edema resulting from retinal vein occlusion (RVO) and diabetic macular edema (DME) — is encapsulated within a nanofibrous matrix fabricated via electrospinning, and said nanofibers are subsequently coated onto a contact lens surface.

To provide antibodies for use in the treatment of ophthalmic vascular diseases such as diabetic macular edema (DME) or macular edema secondary to retinal vein occlusion (RVO).SOLUTION: Provided is a bispecific antibody which binds to human vascular endothelial growth factor (VEGF) and to human angiopoietin-2 (ANG-2), for use in treatment of an ocular vascular diseases selected from neovascular AMD (nAMD) and diabetic macular edema (DME) or of patients suffering from an ocular vascular diseases selected from neovascular AMD (nAMD) and diabetic macular edema (DME). Therein the treatment includes a personalized treatment interval (PTI).SELECTED DRAWING: Figure 1

The invention provides a compound medicine for treating macular edema after cataract phacoemulsification and a preparation method of the compound medicine, and relates to the field of medicines. The compound medicine is prepared from the following raw materials in parts by weight: 18 to 23 parts of herba hedyotidis diffusae, 18 to 23 parts of rhizoma alismatis, 13 to 17 parts of herba artemisiae scopariae, 13 to 17 parts of rhizoma smilacis glabrae, 13 to 17 parts of semen plantaginis, 8 to 12 parts of rhizoma atractylodis, 8 to 12 parts of fructus gardeniae, 10 to 15 parts of white hyacinth bean, 10 to 15 parts of fructus rosae laevigatae, 8 to 12 parts of semen euryales The compound medicine disclosed by the invention is used for treating the macular edema after the cataract phacoemulsification, all the medicines are coordinated and synergistic, the effects of promoting urination and attacking evil, strengthening the spleen and consolidating the foundation, eliminating evil and calming the body resistance are achieved, microcirculation is improved, expression of peripheral blood VEGF (vascular endothelial growth factor) is reduced, vascular permeability is effectively promoted, retina recovery is promoted, and the like. The traditional Chinese medicine composition has a good clinical effect on treating macular edema after cataract ultrasonic emulsification, and has no side effect.

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

The invention discloses an injection composition for treating fundus macular edema and a preparation method thereof, and relates to the technical field of injection compositions. The medicament specifically comprises a medicament A, a medicament B, a medicament C, a medicament D, a medicament E and a medicament F. The medicament A, the medicament B, the medicament C, the medicament D, the medicament E and the medicament F are specifically and respectively composed of trifluoromethasone, bevacizumab, vitamin E, warfarin, lirabel and macacin. The mass percent of the medicament A is 2.2 to 12.5 percent, the mass percent of the medicament B is 4.3 to 33.1 percent, the mass percent of the medicament C is 8.5 to 24.7 percent, the mass percent of the medicament D is 5.5 to 13.2 percent, the mass percent of the medicament E is 7.1 to 26.3 percent, and the mass percent of the medicament F is 6.4 to 23.8 percent. The nano filter membrane is adopted for filtration, microorganisms and particles can be effectively filtered out, and the sterility of a medicine solution is ensured; under the action of an electric field and ultrasonic waves, the motion trails of the microorganisms and the particles can be changed.

The present invention relates to antibodies that bind to VEGF and ANG2 for use in the treatment of ocular vascular diseases such as neovascular AMD (nAMD) (also known as choroidal neovascularization [CNV] secondary to age-related macular degeneration [AMD] or wet AMD), diabetic retinopathy, in particular diabetic macular edema (DME) or macular edema secondary to retinal vein occlusion (RVO).

The invention discloses a biomarker for detecting diabetes mellitus macular edema (DME), a kit for detecting the diabetes mellitus macular edema (DME), and application of the biomarker and the kit for detecting the diabetes mellitus macular edema (DME). The invention provides application of a biomarker in preparation of a reagent or a kit for detecting diabetic macular oedema. The biomarker is selected from one or more of 5-phosphate-beta-D-ribose amine, ascorbic acid glucoside, succinic acid and glutathione disulfide. The potential metabolic marker of DME is identified according to the plasma metabolism type of a DME patient. The biomarker provided by the invention can provide a scientific insight and a new strategy for early diagnosis and intervention of DME.

The invention relates to a traditional Chinese medicine composition for treating macular edema, which is prepared from the following traditional Chinese medicines in parts by weight: 5-35 parts of astragalus mongholicus, 1-30 parts of radix rehmanniae recen, 1-30 parts of radix angelicae, 1-30 parts of rhizoma atractylodis macrocephalae and 1-30 parts of rhizoma atractylodis macrocephalae. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 1-30 parts of poria cocos, 1-20 parts of radix achyranthis bidentatae, 1-20 parts of moutan bark, 1-20 parts of fructus gardeniae, 1-20 parts of radix salviae miltiorrhizae, 1-20 parts of radix scrophulariae, 1-20 parts of radix ophiopogonis, 1-20 parts of radix paeoniae alba, 1-15 parts of radix curcumae, 1-10 parts of radix notoginseng and 1-10 parts of lotus leaves. The traditional Chinese medicine composition can effectively relieve macular edema after macular anterior membrane vitrectomy, has positive effects on improving the inflammatory state, microcirculation and metabolic function of a macular region of a patient, and is safe in clinical use.

An ophthalmic preparation for treating macular edema, optic neuritis and non-infectious endophthalmitis contains an active ingredient for treating eye diseases and an ophthalmic preparation carrier or auxiliary material. The active ingredient for treating eye diseases is a glucocorticoid medicine and / or a non-steroidal medicine. The ophthalmic preparation carrier or auxiliary material contains the following ingredients: a surfactant, an ionic polymer and a solvent, or the ophthalmic preparation carrier or auxiliary material contains the following ingredients: povidone with low polymerization degree, povidone with moderate polymerization degree and a solvent. The ophthalmic preparation can carry (wrap) the glucocorticoid and / or the non-steroidal medicines to penetrate through the anterior segment of eyes and be conveyed to the posterior segment of eyes to treat the macular edema, the optic neuritis and the non-infectious endophthalmitis in an eye drop administration mode, and the ophthalmic preparation has extremely excellent clinical use value and positive social significance.

To provide treatment of AMD using an AAV2 variant with aflibercept.SOLUTION: The present disclosure provides pharmaceutical compositions and methods thereof for treatment of age-related macular degeneration (AMD) in a subject by administering intravitreally a pharmaceutical composition adapted for gene therapy, comprising a vector having a nucleic acid sequence that encodes aflibercept. The present disclosure relates to pharmaceutical compositions and methods for prevention or treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR) in patients with DME, retinal vein occlusion, and related eye diseases or conditions, in a primate or human subject by administering intravitreally or subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector or viral particles (e.g., rAAV) comprising a nucleic acid encoding aflibercept or a functional fragment or variant thereof.SELECTED DRAWING: None

The present disclosure relates to chimeric molecules which are fusion proteins comprising two components: an Ang-2 binding peptide linked to either a VEGF antibody or a VEGF receptor-Fc fusion protein. The Ang2 peptide, VEGF antibody, and VEGF receptor-Fc fusion proteins are each defined below with reference to percent identity to a reference sequence. The chimeric molecule is a fusion protein, dual antagonist of Ang2 and VEGF for treatment of cancers, proliferative retinopathies, neovascular glaucoma, macular edema, AMD, and rheumatoid arthritis.

The invention provides a traditional Chinese medicine composition used in the perioperative period of fundus surgery and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine. The traditional Chinese medicine composition for the perioperative period of the fundus surgery is prepared from the following components in parts by weight: 9 to 15 parts of radix astragali seu hedysari, 6 to 12 parts of radix angelicae sinensis, 6 to 12 parts of radix rehmanniae, 6 to 12 parts of herba ecliptae, 3 to 9 parts of radix paeoniae rubra, 3 to 9 parts of rhizoma atractylodis macrocephalae, 6 to 12 parts of semen plantaginis, 1 to 6 parts of radix saposhnikoviae and 1 to 6 parts of ramulus cinnamomi. By adopting the traditional Chinese medicine composition, the postoperative vision of a patient subjected to fundus surgery can be effectively improved, the retina sensitivity is improved, and the visual function of a macular region is improved; absorption of fundus hemorrhage is effectively promoted, the central fovea thickness of a macular region is reduced, and absorption of postoperative macular edema is promoted; the traditional Chinese medicine composition can improve eye local and whole body traditional Chinese medicine syndromes, and is safe in clinical medication.

The present invention relates to a method for predicting response to an IL-6 antagonist, such as an anti-IL-6 antibody, by determining the concentration of IL-6 in human aqueous humor. The present invention also relates to an IL-6 antagonist for use in treating uveitis or uveitic macular edema.

The present invention relates to novel methods, uses and compositions of annexin A5 protein as combination therapy with one or more anti-VEGF agents, the present invention relates to compounds, for example, for the prevention or treatment of macular edema, retinal vein occlusion and / or one or more diseases, conditions or conditions associated with and / or caused by macular edema or retinal vein occlusion, and / or other conditions suitable for treatment with anti-VEGF agents. In a preferred embodiment, the annexin A5 is administered systemically, such as intravenously.